Menu
Immuno Oncology Europe
Immuno Oncology Europe
Immuno-Oncology Summit Europe
Date: March 20 - 24, 2017
Venue: Hilton Canary Wharf, London, UK

Conference Programs

Novel Approaches for Cancer   Immunomodulatory Approaches  Combination Immunotherapy

Dinner Short Courses

Tuesday, 21 March, 18:30-21:30

Dinner SC1:
New Directions in Cancer Immunotherapy

Dinner SC2:
CAR T and TCR Manufacturing Challenges to Anticipate and Overcome: Focus on How, Where, and Cost Factors
 

Featured Presenters

Roy BaynesRoy D. Baynes, M.D., Ph.D.
Senior Vice President and Head, Global Clinical Development, CMO, Merck Sharp & Dohme

Zelig EshharZelig Eshhar, Ph.D.
Chair, Cancer Immunotherapy, Research and Development, Sourasky Medical Center, Tel Aviv

David FeltquateDavid Feltquate, M.D., Ph.D.
Vice President, Oncology Development, Bristol-Myers Squibb

Dario NeriDario Neri, Ph.D.
Professor, Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH), Zurich

Andy_SewellAndrew Sewell, Ph.D.
Professor, Institute of Infection & Immunity, Cardiff University School of Medicine

Robert WilkinsonRobert W. Wilkinson, Ph.D.
Director, Oncology Research, MedImmune Ltd.

 


About the Event

Following the success of the 2016 conference in London, we present the Immuno-Oncology Summit Europe 2017. Once again our venue is in central London, an ideal meeting place for international academic and industry experts.

Attendees can now experience an entire week of updates and discussion. In Novel Approaches for Cancer we will focus on T cells and their receptors including chimeric antigen receptor (CAR-T) technology, bispecifics, preclinical models, and targets and lead selection. Immunomodulatory Approaches will look at advances in checkpoint inhibitors, agonistic receptor engagement, NK, macrophage and dendritic cell activation, Fc-engineering technologies, cytokine-based therapies and oncolytic vaccines. Combination Immunotherapy will examine design of immunotherapy combinations, combination strategies and provide preclinical and clinical updates.


Attendee Testimonials

"Very stimulatory meeting in an exciting field. Great mix of complementary presentations."

Kerry Chester, Ph.D., Professor, UCL Cancer Institute

"I believe you managed to collate an excellent mix of speakers spanning the most critical aspects of immune oncology, providing an informal forum for discussions between leaders in the field and new investigators coming from both academia and industry."

Björn Frendéus, Ph.D., Chief Scientific Officer, BioInvent International AB

"The content of the meeting was highly relevant and up to date."

Khaterech Ahmadi, Executive Director, MSD-Merck

"The meeting was ideal in terms of size and content. I really enjoyed the conference. It was very insightful and great quality of research was presented."

Sujiet Puthenveetil, Ph.D., Principal Scientist, Medicinal Chemistry, Pfizer, Inc.

Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean

Download Brochure(PDF)